Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial

‒ Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease   ‒ These Phase 2 data reinforce the continued evaluation of mirikizumab in the ongoing, pivotal VIVID Phase 3